Skip to content

US · QURE · BIOTECHNOLOGY

uniQure N.V. (QURE) intrinsic value and stock valuation

$19.35as of 2026-11-21 · Mkt cap 3.22B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

uniQure N.V. DCF and intrinsic value

InvestorsCraft values QURE with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from QURE’s statements →

uniQure N.V. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Amsterdam, NH 1105 BP uniqure.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$16.1M-15.6% 5y CAGRd
20112025
Net income
-$-198.97M
20112025
Free cash flow
-$-177.96M
20112025
Total equity
$198.9M-4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$16.1M$27.1M$15.8M$106.5M$524M
Operating income-$-187.83M-$-184.29M-$-282.87M-$-143.16M$310.6M
Net income-$-198.97M-$-239.56M-$-308.48M-$-126.79M$329.6M
EPSd-$-3.46M-$-4.92M-$-6.47M-$-2.71M$7.04M
Operating cash flow-$-177.96M-$-182.73M-$-145.93M-$-145.06M$288M
Capital expenditure-$-440K-$-3.37M-$-7.15M-$-17.69M-$-17.44M
Free cash flow-$-177.96M-$-186.1M-$-153.08M-$-162.75M$270.5M
Total assets$824.9M$556.5M$831.7M$705M$809.2M
Total debt$536.6M$66.1M$138.4M$142.9M$135.7M
Net debt$456.4M-$-92.87M-$-102.95M-$-85.12M-$-420.53M
Total equity$198.9M-$-6.75M$207.7M$476M$595.8M
Cash and short-term investments$622.5M$367.5M$617.9M$352.8M$556.3M
Income statement
20252024202320222021
Revenue$16.1M$27.1M$15.8M$106.5M$524M
Cost of revenue$1.69M$18.3M$13.6M$3.34M$25M
Gross profit$14.4M$8.79M$2.21M$103.1M$499M
Research and development expenses$140.7M$143.8M$214.9M$197.6M$143.6M
Selling, general and administrative expenses$65.3M$50.7M$73.1M$54.7M$56.3M
Other expenses-$-3.77M-$-1.38M-$-2.86M-$-5.99M-$-11.43M
Operating expenses$202.2M$193.1M$285.1M$246.3M$188.4M
Cost and expenses$203.9M$211.4M$298.7M$249.6M$213.4M
Interest income$17M$21.4M$19.6M$610K$160K
Interest expense$62M$63.7M$41.6M$11.7M$7.47M
Depreciation and amortization$14.8M$12.6M$11.9M$8.54M$7.3M
Ebitda-$-116.59M-$-160.75M-$-253.1M-$-108.02M$319M
Operating income-$-187.83M-$-184.29M-$-282.87M-$-143.16M$310.6M
Total other income/expenses, net-$-5.51M-$-52.83M-$-23.69M$14.9M$22.2M
Income before tax-$-193.34M-$-237.13M-$-306.56M-$-128.26M$332.8M
Income tax expense$5.63M$2.43M$1.92M-$-1.47M$3.22M
Net income-$-198.97M-$-239.56M-$-308.48M-$-126.79M$329.6M
Weighted average shares outstanding$57.5M$48.7M$47.7M$46.7M$46M
Weighted average diluted shares outstanding$57.5M$48.7M$47.7M$46.7M$46.8M
Balance sheet
20252024202320222021
Cash and short-term investments$622.5M$367.5M$617.9M$352.8M$556.3M
Net receivables$5.86M$5.88M$4.19M$102.4M$58.8M
Inventory$0.00$0.00$12M$6.92M$0.00
Total current assets$656M$390.3M$651.9M$476.8M$628.2M
Property, plant and equipment, net$26.3M$34.1M$75.3M$83.3M$69.1M
Goodwill and intangible assets$98.1M$93.5M$86.9M$84.4M$90.3M
Long-term investments$30.2M$27.5M$2.18M$40M$0.00
Total non-current assets$168.9M$166.3M$179.8M$228.2M$180.9M
Total assets$824.9M$556.5M$831.7M$705M$809.2M
Accounts payable$5.17M$7.23M$6.59M$11M$2.5M
Short-term debt$3.86M$3.6M$8.34M$8.38M$5.77M
Deferred revenue$20.5M$0.00$0.00$11.1M$13M
Total current liabilities$62.9M$40.1M$73.7M$75.9M$36.8M
Long-term debt$532.7M$62.5M$130.1M$134.5M$130M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$563.1M$523.2M$550.3M$153M$176.6M
Capital lease obligations$9.83M$14.7M$36.7M$31.7M$29M
Total liabilities$626M$563.3M$624M$229M$213.4M
Common stock$3.69M$2.94M$2.88M$2.84M$2.8M
Retained earnings-$-1.33B-$-1.13B-$-890.41M-$-581.93M-$-455.14M
Accumulated other comprehensive income (loss)-$-58.22M-$-52.8M-$-53.55M-$-58.29M-$-28.86M
Total equity$198.9M-$-6.75M$207.7M$476M$595.8M
Total investments$572.5M$236.1M$378.7M$164.8M$0.00
Total debt$536.6M$66.1M$138.4M$142.9M$135.7M
Net debt$456.4M-$-92.87M-$-102.95M-$-85.12M-$-420.53M
Cash flow statement
20252024202320222021
Net income-$-198.97M-$-239.56M-$-308.48M-$-126.79M$329.6M
Depreciation and amortization$14.8M$12.6M$11.9M$8.54M$7.3M
Stock-based compensation$17.7M$22.3M$35.1M$34.2M$25.6M
Change in working capital-$-6.79M-$-3.94M$81.1M-$-43.38M-$-50.48M
Accounts receivable-$-8.6M-$-2.24M-$-1.32M-$-49.08M-$-58.96M
Inventory$0.00$2.42M-$-6.74M-$-6.92M$0.00
Accounts payable-$-2.67M$1.52M-$-4.17M$9.24M-$-730K
Net cash provided by operating activities-$-177.96M-$-182.73M-$-145.93M-$-145.06M$288M
Investments in property, plant and equipment-$-440K-$-11.69M-$-7.15M-$-17.69M-$-17.44M
Acquisitions, net$0.00$0.00$0.00-$-1.9M-$-49.95M
Net cash used for investing activities-$-321.62M$163M-$-205.69M-$-182.73M-$-67.39M
Common stock issued$391.9M$2.12M$310K$1.45M$33.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$415.4M-$-59.49M$362.7M$1.45M$94.9M
Net change in cash-$-78.69M-$-84.22M$13.4M-$-328.18M$311.7M
Cash at end of period$80.2M$160.3M$244.5M$231.2M$559.4M
Operating cash flow-$-177.96M-$-182.73M-$-145.93M-$-145.06M$288M
Capital expenditure-$-440K-$-3.37M-$-7.15M-$-17.69M-$-17.44M
Free cash flow-$-177.96M-$-186.1M-$-153.08M-$-162.75M$270.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About uniQure N.V.

        uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

        CEO
        Matthew Kapusta
        Employees
        221
        Beta
        0.90

        Explore

        Frequently asked questions

        What is the intrinsic value of uniQure N.V. (QURE)?

        uniQure N.V. (QURE) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is QURE undervalued?

        QURE trades at a price of $19.35 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.